Whorwood C B, Sheppard M C, Stewart P M
Department of Medicine, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, England.
J Steroid Biochem Mol Biol. 1993 Nov;46(5):539-47. doi: 10.1016/0960-0760(93)90180-5.
11 beta-Hydroxysteroid dehydrogenase (11 beta-HSD) by converting active glucocorticoid to an inactive metabolite confers specificity upon the mineralocorticoid receptor (MR) and regulates ligand access to the glucocorticoid receptor (GR). Factors which influence 11 beta-HSD activity seem likely to be of considerable importance in the modulation of both mineralocorticoid and glucocorticoid hormone action. The administration of tri-iodothyronine (T3) to rats has previously been shown to reduce 11 beta-HSD activity in liver but not in kidney. We have studied the effect of T3 on 11 beta-HSD gene expression in vivo in rat liver, kidney, distal colon and pituitary. In addition the effects of T3 on 11 beta-HSD gene expression in vitro in the rat pituitary GH3 cell line have been studied. T3 administration to normal adult rats (40 micrograms/day, s.c. for 1, 3 and 7 days) resulted in a marked decline in liver and pituitary 11 beta-HSD mRNA levels and activity following 3 and 7 days of treatment. These reduced levels were maintained for 3 days following withdrawal of T3 treatment, but returned to control levels after 7 days. In contrast 11 beta-HSD mRNA and activity in kidney and distal colon were unaffected by T3 treatment at each time point studied. In vitro, levels of 11 beta-HSD mRNA and activity in GH3 cells were unchanged following 8, 24 and 72 h treatment with T3 (10(-8) to 10(-6) M). T3 bio-activity was confirmed by a marked dose-dependent decline in the expression of the T3 and glucocorticoid responsive gene, prolactin. T3 inhibits 11 beta-HSD gene expression in both liver and pituitary at a pre-translational level. This effect is absent in the predominantly mineralocorticoid target tissues, kidney and distal colon, i.e. it is tissue specific and as such is consistent with the existence of multiple differentially regulated isoforms of 11 beta-HSD. The time course of the T3 effect in liver and pituitary in vivo and the lack of any effect in vitro suggests that this action is indirect, and not as a result of interaction between the T3 receptor and the putative thyroid hormone response element on the rat 11 beta-HSD gene.
11β-羟类固醇脱氢酶(11β-HSD)通过将活性糖皮质激素转化为无活性代谢产物,赋予盐皮质激素受体(MR)特异性,并调节配体与糖皮质激素受体(GR)的结合。影响11β-HSD活性的因素似乎在盐皮质激素和糖皮质激素作用的调节中具有相当重要的意义。先前已证明给大鼠注射三碘甲状腺原氨酸(T3)可降低肝脏而非肾脏中的11β-HSD活性。我们研究了T3对大鼠肝脏、肾脏、远端结肠和垂体中11β-HSD基因表达的体内影响。此外,还研究了T3对大鼠垂体GH3细胞系中11β-HSD基因表达的体外影响。给正常成年大鼠皮下注射T3(40微克/天,持续1、3和7天),在治疗3天和7天后,肝脏和垂体中的11β-HSD mRNA水平和活性显著下降。在停止T3治疗后,这些降低的水平维持了3天,但7天后恢复到对照水平。相比之下,在研究的每个时间点,肾脏和远端结肠中的11β-HSD mRNA和活性不受T3治疗的影响。在体外,用T3(10^(-8)至10^(-6) M)处理8、24和72小时后,GH3细胞中11β-HSD mRNA和活性水平未发生变化。T3的生物活性通过T3和糖皮质激素反应性基因催乳素表达的显著剂量依赖性下降得到证实。T3在翻译前水平抑制肝脏和垂体中的11β-HSD基因表达。在主要的盐皮质激素靶组织肾脏和远端结肠中不存在这种作用,即它具有组织特异性,因此与存在多种差异调节的11β-HSD同工型一致。T3在体内对肝脏和垂体的作用时间进程以及在体外缺乏任何作用表明,这种作用是间接的,而不是由于T3受体与大鼠11β-HSD基因上假定的甲状腺激素反应元件之间的相互作用。